Ad
related to: trastuzumab trade name- Prescribing Information
Download Prescribing Information
Additional Resources For Physicians
- Request More Information
Be The First To Get Updates
And News About TUKYSA®
- Request A Call Today
Get Updates, Resources & More
Information About TUKYSA®
- Safety Information
Access Clinical Safety Info
Keep Current On News For Physicians
- Prescribing Information
Search results
Results from the WOW.Com Content Network
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [ 31 ] [ 28 ] [ 32 ] [ 33 ] It is specifically used for cancer that is HER2 receptor positive . [ 31 ]
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...
In 2013, trastuzumab emtansine was approved in the United States with the generic name "ado-trastuzumab emtansine", [18] [20] rather than the original United States Adopted Name (USAN) issued in 2009, "trastuzumab emtansine". [20] Trastuzumab is the anti-HER2 antibody; emtansine refers to the linker-drug (SMCC-DM1).
Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1, trade name: Kadcyla, marketed by Genentech and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment with trastuzumab and a taxane chemotherapy. [13] [14]
Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast ...
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
Brenton Wood, the classic soul singer behind hits “The Oogum Boogum Song” and “Gimme Little Sign,” died at the age of 83. Wood’s manager and assistant, Manny Gallegos, confirmed his ...
Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 ... Trastuzumab: Herceptin Biologic Breast cancer: Roche. Genentech. 6,603 265 9
Ad
related to: trastuzumab trade name